Entyvio vs Humira for Ulcerative Colitis: Head-to-Head

Entyvio and Humira are two of the most commonly prescribed biologics for ulcerative colitis, and they represent very different approaches to quieting inflammation. Humira is a systemic anti-TNF that affects immune signaling throughout the body. Entyvio is gut-selective and acts almost exclusively in the intestines. Uniquely for biologic comparisons in UC, there is direct head-to-head randomized trial data. The VARSITY trial compared these two drugs directly, and the results have meaningfully shaped how gastroenterologists think about first-line biologic choice in UC. This guide walks through the evidence patients need to make an informed entyvio vs humira ulcerative colitis decision.

Gut-Selective vs Systemic Mechanism

Humira (adalimumab) is a fully human monoclonal antibody that binds and neutralizes TNF-alpha, a widely distributed inflammatory cytokine. Blocking TNF reduces inflammation throughout the body, including the colon, but also produces broader immunosuppression. Entyvio (vedolizumab) binds the alpha-4-beta-7 integrin, a receptor found almost exclusively on gut-homing lymphocytes, preventing these immune cells from entering inflamed intestinal tissue. Because Entyvio's target is largely confined to the gut, it produces very little systemic immunosuppression. For UC patients, the vedolizumab vs adalimumab UC mechanism choice often centers on whether the extra-intestinal coverage of anti-TNFs is needed or whether a narrower gut-targeted approach fits better.

VARSITY Trial: The Head-to-Head Data

VARSITY was a phase 3b double-blind randomized trial that directly compared vedolizumab and adalimumab in 769 adults with moderate-to-severe UC. Published in the New England Journal of Medicine in 2019, the trial ran for 52 weeks and measured clinical remission, endoscopic improvement, and corticosteroid-free remission. At week 52, 31.3% of vedolizumab patients achieved clinical remission compared with 22.5% of adalimumab patients, a statistically significant difference (p=0.006). Endoscopic improvement rates were 39.7% for vedolizumab and 27.7% for adalimumab. Corticosteroid-free remission was one area where the two drugs performed more similarly, with adalimumab numerically ahead. VARSITY established that Entyvio delivers superior clinical and endoscopic outcomes to Humira in biologic-naive UC patients over one year.

Onset of Action and Induction

Humira still offers a faster onset of symptom improvement than Entyvio. Many adalimumab patients report clinical response within the first few weeks of induction. Entyvio is notably slower, with some patients not reaching meaningful response until week 10 to 14 and continuing to improve through week 26. For UC patients with severe, active symptoms who need rapid symptom control, Humira's early response often matters clinically. For patients in a less acute state or those who have already failed an anti-TNF, Entyvio's slower but more sustained trajectory is usually manageable. VARSITY measured 52-week outcomes, so the trial does not speak directly to short-term symptom relief during induction.

Safety and Infection Risk

Safety is an area where Entyvio consistently performs well. In VARSITY, serious infection rates were 1.6% for vedolizumab and 1.9% for adalimumab. Exposure-adjusted infection rates have been lower on Entyvio in multiple registry studies, and its gut-selective mechanism does not meaningfully increase systemic infection risk. A 2024 Swedish registry study flagged a higher rate of serious gastrointestinal infections on vedolizumab compared with anti-TNFs in Crohn's, but UC-specific data from VARSITY and pooled analyses has generally shown a cleaner overall infection profile with Entyvio. Neither drug carries the progressive multifocal leukoencephalopathy risk that defines natalizumab, and both require TB and hepatitis B screening before starting.

Dosing and Administration

Humira is a subcutaneous injection throughout. Induction is 160 mg on day 1 and 80 mg on day 15, with maintenance of 40 mg every other week, per AbbVie's prescribing information. Entyvio begins with three 300 mg IV infusions at weeks 0, 2, and 6, followed by maintenance every 8 weeks, per Takeda's dosing information. After IV induction, patients who respond by week 6 can switch to a 108 mg subcutaneous pen every 2 weeks. For UC patients who prefer all home-based injection, Humira is simpler. For patients who want less frequent maintenance (every 8 weeks IV) or the flexibility to switch between IV and SC, Entyvio's schedule offers more options over the long term.

Biologic-Experienced Patients

VARSITY enrolled mostly biologic-naive patients, so its results primarily apply to UC patients starting a first biologic. For UC patients who have already failed an anti-TNF, Entyvio produces meaningful remission in a subset of patients, though response rates are lower than in the biologic-naive setting. Real-world cohorts suggest that switching from Humira to Entyvio after anti-TNF failure delivers better response than cycling to a second anti-TNF, though response rates in either direction remain modest. Gastroenterologists often consider the mechanism change the key benefit of switching classes rather than cycling within anti-TNFs.

Choosing With Your GI

VARSITY has made Entyvio a strong first-line candidate for many biologic-naive UC patients, particularly those prioritizing safety or long-term remission. Humira remains a reasonable choice for patients with concurrent extraintestinal manifestations, those who want all-SC administration, or those for whom adalimumab biosimilars have the clearest insurance coverage. Ask your GI how response will be measured at the standard assessment points (around week 14 for Entyvio and week 8 for Humira), what to do if symptoms persist, and whether an immunomodulator will be paired with your biologic. A simple log of stool frequency, urgency, blood, and any new symptoms between visits gives your care team the data they need to recognize partial response or early loss of response before a full flare returns.